Back to Education Zone

touchCONGRESS Webinar

Continuing the conversation with CDK4/6 inhibitors in advanced breast cancer from SABCS 2018

Introduction

Stay up-to-date with the latest advances in advanced breast cancer with our expert summary from the San Antonio Breast Cancer Symposium (SABCS) 2018 Congress, 3—8 December 2018.

Professor Stephen Johnston (The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London) reviews the most pertinent emerging data presented at the SABCS 2018 Congress and discusses their potential impact on everyday clinical practice.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After watching this touchCONGRESS Webinar, you should be able to:

 

  • Recognize the challenges physicians face in the management of advanced breast cancer, with a focus on HR+/HER2- disease.
  • Be aware of key clinical data presented at SABCS 2018 for advanced breast cancer, including CDK4/6 inhibitors and other targeted therapies, with a focus on efficacy, tolerability, quality of life and any prognostic factors for their use (both patient and disease).
  • Understand the impact that these data may have for optimizing clinical practice and patient outcomes, with a focus on treatment sequencing.

Clinical Spotlight

  • Where are we now with the current management of HR+/HER2- advanced breast cancer? Focus on challenges for optimizing treatment sequencing.

  • What new data for CDK4/6 inhibitors were presented at SABCS 2018? Focus on efficacy and securing optimal cancer care.   

  • What other breaking data with novel therapies for advanced breast cancer were presented at SABCS 2018? Focus on the future treatment landscape.

Please feedback on this touchCONGRESS Webinar on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).

Prof. Stephen Johnston

Stephen Johnston is Professor of Breast Cancer Medicine and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden from 2007 to 2012, and is currently Clinical Director of the Breast, Lung and AOS Clinical Business Unit at The Royal Marsden.

He graduated in 1983 from Trinity College at the Cambridge University, and in 1986 from the Medical School at the University of Newcastle-upon-Tyne. He trained in general medicine at St Bartholomew’s Hospital and Hammersmith Hospital in London, and subsequently in medical oncology at The Royal Marsden. He gained his PhD from The Institute of Cancer Research at the University of London, and took up his current position as Consultant Medical Oncologist in the Breast Unit at The Royal Marsden in 1997.

He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase II/III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors.

He has published over 250 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national and international meetings. He is a member of several scientific committees and advisory boards, a prior Faculty member at the American Society for Clinical Oncology, a current member of San Antonio Breast Cancer Symposium abstract review committee, and serves as Deputy/Associate Editor for the international journals ‘Breast Cancer Research’ and ‘Clinical Breast Cancer’.

Disclosures: Consultancy for Eli Lilly, AstraZeneca and Puma Biotechnology. Member of speakers’ bureaux for Pfizer and Novartis. Institutional research funding from Pfizer.

touchCONGRESS Expert Opinions

Watch a series of internationally renowned clinical specialists from Europe and Japan discuss key clinical data for advanced breast cancer from SABCS 2018 and their potential implications for optimizing patient outcomes, from both global and regional perspectives.

Watch Now